Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169454 | 1.00 | ESR1 (0.40) | ESR1ESR2HSD17B10ALDH1A1KMT2A | |
| SCHEMBL11279849 | 0.83 | ALDH1A1 (0.47) | ESR1ESR2ALDH1A1KMT2AMEN1 | |
| SCHEMBL31753689 | 0.83 | ALDH1A1 (0.47) | ESR1ESR2ALDH1A1KMT2AMEN1 | |
| SCHEMBL1467659 | 0.82 | HPGD (0.42) | ESR1ESR2HSD17B10ALDH1A1KMT2A | |
| SCHEMBL3192065 | 0.81 | SKP2 (0.47) | ESR1ESR2ALDH1A1KDM4EGAA | |
| SCHEMBL29427134 | 0.79 | ALDH1A1 (0.39) | ESR1ESR2ALDH1A1KMT2AMEN1 | |
| SCHEMBL308275 | 0.79 | ALDH1A1 (0.39) | ESR1ESR2ALDH1A1KMT2AMEN1 | |
| SCHEMBL10871333 | 0.79 | TRPA1 (0.43) | ESR1ESR2ALDH1A1KMT2AMEN1 | |
| SCHEMBL1045835 | 0.78 | CA2 (0.38) | HSD17B10CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL93048 | 0.78 | S1PR1 (0.47) | ESR1ESR2HSD17B10ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250145629-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| CN-119325465-A | Biphenyl substituted epithelial sodium channel blocking compounds | 帕里昂科学公司 | 2025-01-17 | — | — | CN | disclosed |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024233665-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240368123-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| CN-118344338-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2024-07-04 | — | — | US | disclosed |
| US-5516777-A | PROSTATE CANCER THERAPY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-14 | — | — | US | disclosed |
| US-5409928-A | Prostate diseases, alopecia | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| US-5356893-A | Antidepressants, nervous system disorders | GLAXO GROUP LIMITED (GB) | 1994-10-18 | — | — | US | disclosed |
| CN-1089944-A | The N-Benzanilide derivatives | GLAXO GROUP LTD (GB) | 1994-07-27 | — | — | CN | disclosed |
| CN-1089609-A | Pyrazole-fused ring derivatives, its manufacture method and male hormone inhibitor | OTSUKA PHARMA CO LTD (JP) | 1994-07-20 | — | — | CN | disclosed |
| CN-1089260-A | Trisubstituted biphenyls | BAYER AG (DE) | 1994-07-13 | — | — | CN | disclosed |
| EP-0594019-A1 | Trisubstituted biphenyl as angiotensin II antagonistes | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
| EP-0594149-A2 | Condensed pyrazole derivatives, method of manufacturing the same, and androgen inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-27 | — | — | EP | disclosed |
| CN-1071922-A | The N-Benzanilide derivatives | GLAXO GROUP LTD (GB) | 1993-05-12 | — | — | CN | disclosed |
| EP-0533266-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | ESR1 4612/4885ESR2 3009/4885HSD17B10 1056/4885 |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | ESR1 3382/4885ESR2 2729/4885HSD17B10 2180/4885 |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | ESR1 4679/4885ESR2 2672/4885HSD17B10 1868/4885 |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | ESR1 2007/4885ESR2 365/4885HSD17B10 500/4885 |
| US-20250145629-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | ESR1 4544/4885ESR2 2968/4885HSD17B10 1136/4885 |
| US-20240368123-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | REN, BDKRB2, BDKRB1 | ESR1 2643/4885ESR2 1023/4885HSD17B10 1613/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | ESR1 4612/4885ESR2 3009/4885HSD17B10 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.